Orgenesis appoints industry veteran Mario Philips to its board of directors

Published On: 14 Jan 2020

Germantown, MD, US, January 13, 2020 Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary MTH Global, Inc., as well as localized point-of-care development and processing centers, today announces that Mario Philips was appointed to Orgenesis’ board of birectors.

Mario Philips is chief executive officer of PolyNeuroS, a drug company based in France that has developed a diagnostic platform technology for neurodegenerative diseases in combination with a therapy to cure neurodegenerative diseases such as ALS and Parkinson’s. Mr. Philips also acts as strategic partner for the private equity fund, Archimed, and is chairman of the board for its portfolio company, Clean Biologics. Prior to that, in 2017 Mr. Philips acted as vice president and general manager for Danaher Pall’s (“Pall”) biotech business, with full P&L responsibility for a USD 1.3 billion business unit. He was promoted from the role of Vice President and General Manager of Pall to lead the Single-Use Technologies BU. Mr. Philips joined ATMI in 1999 with ATMI’s acquisition of MST Analytics, Inc., serving as European sales manager for ATMI Analytical Systems. In 2004, Mr. Philips was appointed as general manager of ATMI Packaging, a role he held through 2010 when he was promoted to the position of senior vice president and general manager, ATMI Life Sciences. In that role, he was responsible for developing and executing all business strategies, including the introduction of new products and service solutions for the life sciences industry. A strong leading innovative IP portfolio was created and Pall acquired the business in 2014. Mr. Philips also held several board member positions in the life sciences industry with Austar Life Sciences (China), Disposable Lab (France) and Artelis (Belgium). Mr. Philips earned an engineering degree in Biochemistry at CTL, Gent, and has a postgraduate degree in Marketing from Groep T Leuven.

Vered Caplan, CEO of Orgenesis, stated, “We are excited to welcome Mario to the board of directors. Mario brings over 25 years of operational experience and extensive relationships within the life sciences and bioprocessing sectors, which should be invaluable in advancing our point-of-care (“POCare”) cell therapy platform and continuing to grow our Contract Development and Manufacturing Organization (“CDMO”) business. Additionally, we believe having such highly respected industry leader will assist us in pursuing collaboration and in-licensing opportunities to speed the development, lower costs and accelerate the path to market for transformative and lifesaving cell and gene therapies.”

About Orgenesis

Orgenesis is a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates through two platforms: (i) a point-of-care (“POCare”) cell therapy platform (“PT”) and (ii) a Contract Development and Manufacturing Organization (“CDMO”) platform conducted through its subsidiary, Masthercell Global. Through its PT business, the Company’s aim is to further the development of Advanced Therapy Medicinal Products (“ATMPs”) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients. The Company out-licenses these ATMPs through regional partners to whom it also provides regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting. Through the Company’s CDMO platform, it is focused on providing contract manufacturing and development services for biopharmaceutical companies. Additional information is available at: www.orgenesis.com.

Related links